News Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
3.45 ^USD	+10.58%		+8.15%	-21.23%

17/04	Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	CI
15/04	Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	17/04	CI
Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	15/04	CI
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE	25/03	AQ
Sector Update: Health Care Stocks Steady Pre-Bell Friday	22/03	MT
Sector Update: Health Care	22/03	MT
Eton Pharmaceuticals Acquires U.S. Rights to PKU GOLIKE from Relief Therapeutics Holding SA	22/03	CI
Eton Pharmaceuticals Acquires US Rights to Phenylketonuria Dietary Management Product	22/03	MT
Relief Therapeutics Grants Eton Pharmaceuticals Exclusive License for US Commercialization of Golike	22/03	MT
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria	22/03	AQ
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria	22/03	GL
Transcript : Eton Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 14, 2024	15/03
Eton Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Earnings Flash (ETON) ETON PHARMACEUTICALS Posts Q4 Revenue $7.3M, vs. Street Est of $7.66M	15/03	MT
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	15/03	GL
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024	01/03	GL
Eton Pharmaceuticals' ET-400 Protect Candidate Approved for US Patent	21/02	MT
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	21/02	GL
Eton Pharmaceuticals Awards U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation	21/02	CI
Eton Pharmaceuticals Says Nitisinone Capsules Now Commercially Available in US	03/02	MT
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules	02/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Summary

Filters